These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17964981)

  • 1. [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
    Thomas X
    Bull Cancer; 2007 Oct; 94(10):871-80. PubMed ID: 17964981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Piccaluga PP; Paolini S; Martinelli G
    Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
    Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 6. Circumventing resistance to kinase-inhibitor therapy.
    Druker BJ
    N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
    Santos FP; Cortes J
    Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. As leukemia options grow, drugs jockey to be first-line therapies.
    Dolgin E
    Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [KIT and KIT: from biology to clinical use].
    Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
    Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A; Bui B
    Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
    Kujawski L; Talpaz M
    Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Focus on GIST management].
    Tardieu M; Dômont J; Cioffi A; Bonvalot S; Le Cesne A
    Bull Cancer; 2010 Jun; 97(6):723-31. PubMed ID: 20483709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stock W
    Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
    Fullmer A; Jabbour E
    Am J Hematol; 2010 Mar; 85(3):158-9. PubMed ID: 20131307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.